Pretty much immediately, the early investors were in the red. Chuck Triano +1 (212) 733-7410[emailprotected] Pharma Atea Pharmaceuticals (AVIR -0.61%)reported interim phase 2 results at the end of June showing that its lead COVID-19 oral treatment, AT-527, could rapidly reduce the viral load in COVID-19 patients. Thats a hard pill to swallow. However, it could also be used to monoclonal antibodies, peptides, and nucleic acids rather than using an injection. These statements involve known and unknown risks, uncertainties and other factors that could cause Progenitys actual results to differ materially from the forward-looking statements expressed or implied in this press release, including Progenitys ability to successfully develop and commercialize its products under development, the uncertainties inherent in the development process, such as the regulatory approval process, the timing of regulatory filings, and other matters, including the ongoing COVID-19 pandemic, that could affect sufficiency of existing cash, cash equivalents and short-term investments to fund operations and the availability or commercial potential of Progenitys products, and those risks described in Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations in Progenitys Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 18, 2021, and other subsequent documents we file with the SEC, including but not limited to Progenitys Quarterly Reports on Form 10-Q. Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile. Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology. Progenity: Don't Bet on This Biotech Firm Yet - InvestorPlace The case highlights how equitable global access will require better advance planning by drugmakers, governments and health organizations, health officials say. In an interview last month, Pfizer's head of vaccines research and development Annaliesa Anderson said the company still aimed to make its vaccine the first of its kind available for pregnant women in low-income countries more or less in the "same time frame" as in wealthy countries. Not long ago, InvestorPlace contributor Chris MacDonald reported that the short interest in PROG stock had spiked in recent weeks. Thats true: the short interest in Progenity shares literally doubled from the end of August to mid-September. Thats promising. InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Further data from the ongoing Phase 1/2 clinical trials of the four vaccine candidates will enable the selection of a lead candidate and dose level for an anticipated large, global Phase 2b/3 safety and efficacy study that may begin as early as later this month, pending regulatory approval. Media Relations As part of its GI-targeted therapeutics program, Progenity is preparing to initiate early clinical studies of its PGN-600 program for targeted delivery of a proprietary formulation of tofacitinib . Does progenity own the patent for Pfizer's paxlovid delivery? - Reddit
I Arete Inc Georgia,
Port Aransas Live Music,
1 Bedroom Flat To Rent Penryn,
Talking Heads This Must Be The Place,
Stan Cole Fbi Real,
Articles P
